Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Trial to Explore Potential Benefit of ARD-301 for Patients Suffering from the Sequelae of Chronic Post-COVID Syndrome

Next Previous
Trial Profile

A Phase 2 Trial to Explore Potential Benefit of ARD-301 for Patients Suffering from the Sequelae of Chronic Post-COVID Syndrome

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 26 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone (Primary)
  • Indications Post acute COVID 19 syndrome
  • Focus Therapeutic Use

Most Recent Events

  • 25 Apr 2023 According to a Scilex Holding media release, this study expected to be initiated in 2023
  • 08 Mar 2021 New trial record
  • 01 Mar 2021 According to a Sorrento Therapeutics media release, Stephen Faraone, Ph.D. (Distinguished Professor and Vice Chair for Research, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York) looks forward to working with Sorrento, Scilex Holding, and Aardvark Therapeutics to initiate this Phase 2 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top